

Exercise training for people following curative intent treatment for non-small cell lung cancer: A randomised controlled trial

Short title: Exercise training in people with lung cancer

VINICIUS CAVALHERI,^{1,2} SUE JENKINS,^{1,2,3} NOLA CECINS,^{2,3,4} KEVIN GAIN,^{5,6} MARTIN J PHILLIPS,⁷ LUCAS H SANDERS,⁸ KYLIE HILL^{1,2,9}

¹ School of Physiotherapy and Exercise Science, Faculty of Health Sciences, Curtin University, Perth, WA, Australia

² Institute for Respiratory Health, Sir Charles Gairdner Hospital, Perth, WA, Australia

³ Physiotherapy Department, Sir Charles Gairdner Hospital, Perth, WA, Australia

⁴ Community Physiotherapy Services, Perth, WA, Australia

⁵ Department of Respiratory Medicine, Royal Perth Hospital, Perth, WA, Australia

⁶ School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia

⁷ Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia

⁸ Department of Cardiothoracic Surgery, Sir Charles Gairdner Hospital, Perth, WA, Australia

⁹ Physiotherapy Department, Royal Perth Hospital, Perth, WA, 6001, Australia

Corresponding author

Dr. Vinicius Cavalheri

School of Physiotherapy and Exercise Science, Faculty of Health Sciences, Curtin University

GPO Box U1987, Perth, Western Australia, 6845

Phone number: +61(8) 9266 4043

Email address: vinicius.cavalher@curtin.edu.au

Keywords (English): Lung neoplasms; carcinoma, non-small cell; exercise training; rehabilitation.

Abstract

Objective: In people following curative intent treatment for non-small cell lung cancer (NSCLC), to investigate the effects of supervised exercise training on exercise capacity, physical activity and sedentary behaviour, peripheral muscle force, health-related quality of life (HRQoL), fatigue, feelings of anxiety and depression and lung function. **Method:** This pilot randomised controlled trial included participants 6-10 weeks after lobectomy for NSCLC or, for those who required adjuvant chemotherapy, 4-8 weeks after their last cycle. Participants were randomised to either 8 weeks of supervised exercise training (exercise group) or 8 weeks of usual care (control group). Prior to and following the intervention period, both groups completed measurements of exercise capacity, physical activity and sedentary behaviour, quadriceps and handgrip force, HRQoL, fatigue, feelings of anxiety and depression and lung function. Intention-to-treat analysis was undertaken. **Results:** Seventeen participants (mean age 67, SD=9yr; 12 females) were included. Nine and eight participants were randomised to the exercise and control groups, respectively. Four participants (44%) adhered to exercise training. Compared with any change seen in the control group, those in the exercise group demonstrated greater gains in the peak rate of oxygen consumption (mean difference, 95% confidence interval [CI] for between-group difference: 0.19 [0.04 to 0.33]L/min) and six-minute walk distance (52 [12 to 93]m). No other between-group differences were demonstrated. **Conclusions:** In people following curative intent treatment for NSCLC, 8 weeks of supervised exercise training improved exercise capacity, measured by both laboratory- and field-based exercise tests. These results suggest that this clinical population may benefit from attending exercise training programmes.

Trial registered the Australian New Zealand Clinical Trials Registry (ACTRN12611000864921).

Bullet points

- Lung resection for lung cancer is associated with marked reductions in exercise capacity
- Exercise training increased exercise capacity in people with non-small cell lung cancer
- Exercise training did not improve other outcomes

Introduction

Lung cancer is the leading cause of death for malignancy worldwide¹. Data from the Australian Institute of Health and Welfare revealed that the 5-year survival of people with lung cancer is 15%². In people diagnosed with lung cancer, 85% of cases are non-small cell lung cancer (NSCLC)³. Importantly, for people diagnosed with early stage NSCLC, surgical resection of the tumour, with or without adjuvant chemotherapy, is considered to be a curative intent treatment⁴, and the 5-year survival of people following lung resection is up to 80%⁴.

Lung resection is associated with marked reductions in exercise capacity (i.e. peak rate of oxygen consumption [VO_{2peak}])⁵⁻⁷ and health-related quality of life (HRQoL)^{8,9}. Although there is strong evidence that exercise training improves exercise capacity and HRQoL in people with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD)¹⁰ and interstitial lung disease¹¹, there are few studies investigating the role of exercise training for people who have recently completed curative intent treatment for NSCLC. Preliminary data suggests that exercise training may play an important role for individuals with a variety of cancer diagnoses^{12,13}. A recent Cochrane systematic review, that included three randomised controlled trials (RCT) of exercise training in people following lung resection for NSCLC, demonstrated an increase in 6-minute walk distance (6MWD)¹⁴. However, this finding needs to be interpreted with caution due to methodological shortcomings of the included studies, such as lack of computer generated randomisation sequence and blinding of outcome assessors, per-protocol analysis and selective reporting of results. Further, in the three studies included in the review, outcome measures were limited to exercise capacity, muscle strength and HRQoL.

Therefore the aim of this pilot study was to investigate the effects of supervised exercise training on a wide range of outcomes such as exercise capacity, physical activity and sedentary behaviour, peripheral muscle force, HRQoL, fatigue, feelings of anxiety and depression and lung function in people following curative intent treatment for NSCLC. We sought to use a design that would overcome some of the methodological shortcomings evident in earlier work by concealing the computer generated

randomisation sequence, blinding the outcome assessor and analysing the data according to intention-to-treat (ITT) principle.

Methods

Study design and participants

This study was a pilot single-blinded RCT approved by the Ethics Committees of Sir Charles Gairdner Hospital (SCGH) and Royal Perth Hospital (RPH), Perth, WA, Australia (approval numbers 2011/105 and RA-11/033) and Curtin University, Perth, WA, Australia (approval number HR178/2011). The trial was prospectively registered (15/08/2011) with the Australian New Zealand Clinical Trials Registry (ACTRN12611000864921).

Data collection was performed between February-2012 and April-2014. Measurements were collected in people 6-10 weeks after lobectomy for NSCLC (stages I-IIIa) or, for those who required post-operative chemotherapy, 4-8 weeks after their last chemotherapy cycle. Exclusion criteria comprised: presence of any co-morbid condition that could compromise safety during assessments; severe neuromusculoskeletal limitations; participation in a programme of supervised exercise training in the last 3 months and; inability to understand spoken or written English. Participants were recruited from outpatient clinics and referrals to the pulmonary rehabilitation programmes at two hospitals and a private thoracic surgery clinic.

Protocol and measurements

After obtaining written informed consent, baseline assessments were undertaken over 2-3 days, with a minimum of 24 hours between each assessment day. Participants were then randomised to an exercise group (EG), or a control group (CG). The randomisation sequence was generated and managed by an independent researcher using a computer and concealed using sequentially numbered opaque envelopes. The sequence was stratified according to the hospital from which the participant was recruited and for the use (or not) of adjuvant chemotherapy.

Participants were reassessed on completion of the 8-week intervention period. The primary outcome was exercise capacity. Secondary outcomes comprised physical activity and sedentary behaviour, peripheral muscle force, HRQoL, fatigue, feelings of anxiety and depression and lung function. The primary investigator, who was responsible for the baseline and post-intervention period assessments, was not aware of whether a participant had been allocated to the EG or the CG. For both baseline and post-intervention period assessments, the first and second assessment days took place at the hospital at which the participants had received their treatment.

Measurements performed on the first assessment day were:

- (i) 6MWD (45-m straight course within an enclosed corridor. Two tests, separated by a 30-minute rest period, were conducted and the best 6MWD was recorded as the test result)^{15,16}.
- (ii) HRQoL (Medical Outcomes Study Short-Form 36 general health survey (SF-36)¹⁷, Functional Assessment of Cancer Therapy – Lung scale (FACT-L)¹⁸, and European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 [EORTC QLQ-C30]¹⁹).
- (iii) Feelings of anxiety and depression (Hospital Anxiety and Depression Scale [HADS]²⁰).
- (iv) Fatigue (Functional Assessment of Chronic Illness Therapy - Fatigue subscale [FACIT-Fatigue]²¹).
- (v) Isometric handgrip force (measured using a hydraulic hand dynamometer [Jamar; JA Preston Corporation; USA]). Peak handgrip force was assessed bilaterally, with the elbow at 90° flexion and the forearm and wrist in a neutral position²².

Participants were also given two physical activity monitors (the SenseWear armband^{23,24} and the Stepwatch activity monitor²⁵) to be worn over 7 consecutive days. A minimum of 4 full days of data (defined as ≥ 10 hours/day of monitoring), including one weekend day, were required for participants' data to be included in analyses. Data on energy expenditure (i.e. metabolic equivalent units [MET]), provided by the SenseWear armband, and daily step count, provided by the Stepwatch, were averaged for analysis. Using measures of MET derived from the the SenseWear armband, proportion of time spent in

three domains were calculated: (i) sedentary behaviour (≤ 1.5 MET); (ii) light intensity physical activity (> 1.5 and ≤ 3 MET); and (iii) moderate-to-vigorous intensity physical activity (> 3 MET)²⁶.

Following the completion of 7 days of activity monitoring, participants returned for the second assessment day, during which measures were made of spirometry, lung volumes and gas transfer²⁷⁻³⁰. The Medgraphics Elite Series DX plethysmograph (Medical Graphics Corporation, USA) was used.

Thereafter, a symptom-limited ramp cycle-ergometry cardiopulmonary exercise test (CPET) was undertaken on an electronically braked bicycle ergometer (Corival; Lode, The Netherlands) in accordance with published guidelines³¹. Breath-by-breath measurements were collected (Ultima™ CardiO2®; MGC-Diagnostics, USA). Blood pressure was measured every 2 minutes by automated sphygmomanometry. Twelve-lead electrocardiography was used and arterial oxygen saturation measured via pulse oximetry (SpO₂) was continuously monitored (Radical; Masimo Corporation, USA). The modified BORG scale (0-10) was used to quantify dyspnoea and leg fatigue prior to starting the test, each minute during the test, and on test completion. Measures were collected of peak rate of oxygen consumption (VO_{2peak}), VO₂ at the anaerobic threshold (AT) maximum work rate (W_{max}) and oxygen pulse (O₂ pulse), which was calculated by dividing the VO_{2peak} by the maximal heart rate³¹. The W_{max} and measures of VO_{2peak} were expressed in absolute values and as a percentage of the predicted value in a healthy population³².

The third assessment day comprised the measurement of isometric quadriceps muscle torque³³. It was performed on upright seated position, using the HUMAC NORM isokinetic dynamometer (CSMi; Stoughton, USA). The dominant leg was chosen and participants were asked to perform five maximum contractions of the quadriceps at 60° knee flexion. Each contraction was separated by 60 seconds. The contraction that generated the highest torque, and was within 5% of another effort, was recorded as the test result. Measures were expressed in absolute values and as a percentage of the predicted value in a healthy population³³. The measurement of isometric quadriceps muscle torque took place at the University. As the University is approximately 15km from either of the hospitals, participants were given the option to decline this assessment.

Exercise group

Participants in the EG underwent an 8-week exercise training programme aimed at improving aerobic capacity and muscle strength. This programme was embedded within the exercise training programmes at SCGH and RPH. It comprised individual, supervised training three times per week delivered by senior physiotherapists. Each session was 60 minutes in duration. In the event that a participant could only attend two supervised sessions per week, they were provided with a cycle ergometer (OBK600A; Orbit fitness equipment, Perth, WA, Australia) to use at home for one training session per week. Each class comprised aerobic (walking/cycling) and resistance training (upper/lower limbs). Adherence to exercise training was defined as a completion rate of $\geq 60\%$ of training sessions (i.e. ≥ 15 training sessions) and reported by the senior physiotherapists to the investigators.

Participants walked in 100-m long corridor or on a treadmill for 20 minutes. For corridor walking, the initial average speed was set at 80% of the average 6MWT speed³⁴. For instance, for someone with a baseline 6MWD=450m, walking goal was calculated as follows:

6MWD=450 m \rightarrow average speed=4.5km/h \rightarrow initial speed=3.6km/h. Therefore, during the 20 minutes of walking, this person would be instructed to walk 1,200m (i.e. 6 laps).

For treadmill walking, the initial average speed was set at 70% of the average 6MWT speed³⁴. Average walking speed was increased if the participant was able to walk for 20 minutes continuously providing symptoms and SpO₂ were within acceptable limits ($\geq 88\%$). Cycling consisted of 10 minutes of endurance training (initial work rate was set at 60% of the W_{max} achieved during the CPET) and two periods of 2 minutes of power training (initial work rate was set at 80% of the W_{max} achieved during the CPET performed at the baseline assessment).

The resistance training comprised step-ups (undertaken within parallel bars in two sets of 10 repetitions) and exercises with hand weights for the biceps brachii muscle (elbow flexion) and deltoid muscle (short-lever shoulder abduction). Upper limb training was undertaken in three sets of 10 repetitions (initial weights: 1.5 kg for women and 2 kg for men).

Control group

Participants in the CG were instructed to continue to perform their usual activities during the period of the study. They received weekly phone calls from a research assistant which consisted of general conversation as well as standardised questions about their health and well-being. These phone calls allowed the investigators to maintain contact with those in the CG and optimise their retention in the study and also served to minimise bias resulting from differences in attention provided by the investigators to the participants during the intervention period.

Statistical analyses

Statistical analyses were performed using SPSS® (Statistical Package for Social Sciences, version 22.0). As this is a pilot RCT, sample size was determined by the number of participants recruited during the period allowed for commencement and completion of the study (i.e. from February 2012 to April 2014). Analyses were undertaken according to the intention-to-treat principle. The distribution of data was analysed via frequency histograms and the Shapiro-Wilk test. For normally distributed data, both within- and between-group differences were assessed using two-way repeated measures ANOVA. Between-group differences are reported as the mean difference and 95% confidence interval (CI) (F values are provided in the Tables). Regarding non-normally distributed data, within-group differences were assessed using a Wilcoxon test whereas between-group differences were assessed using a Mann-Whitney test. For all analyses, a p value <0.05 was considered significant. Data are expressed as either mean \pm standard deviation or median [interquartile range].

Results

The study flow diagram is presented in Figure 1. Seventeen participants (12 females) were randomised to the EG (n=9) or the CG (n=8). Baseline characteristics of the participants are summarised in Table 1.

Of the nine participants randomised to the EG, four (44%) adhered to exercise training by completing 15 or more training sessions (i.e. $\geq 60\%$). The mean number of sessions that these four participants completed was 17 ± 3 . Of the remaining five participants, one completed 10 sessions and stopped training as they contracted pertussis. One participant completed four sessions and another completed six sessions. Both stopped training as they felt unwell. They completed some of the post-intervention assessments and were later diagnosed with a primary cancer other than lung cancer. One participant completed four sessions and decided to cease training stating they were too busy. The final participant declined participation in exercise training as they were unwilling to travel to the hospital. In order to facilitate ITT analysis, all participants were encouraged to attend the post-intervention assessments, regardless of their adherence with the exercise training.

Regarding the phone calls scheduled for those in the CG, three participants were available for all eight calls, one participant was available for six calls, two participants were available for five calls and two participants were available for four calls. The reasons for missing phone calls were that they were either away on vacation or busy with family-related responsibilities. In order to facilitate ITT analysis, all participants were encouraged to attend the post-intervention assessments, regardless of their adherence with the phone calls.

Primary outcome - Exercise capacity

Baseline and post-intervention period measures are presented in Table 2.

Cardiopulmonary exercise test

At baseline, the $\text{VO}_{2\text{peak}}$ of the EG and the CG was 62 ± 18 and $64\pm 17\%$ pred, respectively ($p=0.74$ for between-group difference). Compared with any change observed in the CG, greater gains were demonstrated in the EG in $\text{VO}_{2\text{peak}}$ (mean difference [95% CI] $0.19[0.04 \text{ to } 0.33]\text{L}\cdot\text{min}^{-1}$), O_2 pulse ($2[0 \text{ to } 3]\text{ml}\cdot\text{beat}^{-1}$) and AT ($11[1 \text{ to } 21]\%$ of $\text{VO}_{2\text{peak}}$).

Six-minute walk test

At baseline, the 6MWD of the EG and the CG was 88 ± 9 and $77\pm 11\%$ pred, respectively ($p=0.09$ for between-group difference). Compared with any change observed in the CG, greater gains were demonstrated in the EG in 6MWD (mean difference [95% CI of difference] $52[12 \text{ to } 93]\text{m}$).

Secondary outcomes

On completion of the intervention period, no between-group differences were observed in light intensity physical activity, moderate-to-vigorous intensity physical activity, sedentary behaviour and daily steps (Table 3). At baseline, isometric quadriceps torque and isometric handgrip force in both groups were $> 90\%$ pred (Table 3). On completion of the intervention period, no between-group differences were observed in these outcome measures (Table 3).

No between-group differences were observed in the component summary scores or individual domains of the SF-36, the scores of the FACT-L and EORTC QLQ-C30 (Table 4).

No between-group differences were observed in fatigue (FACIT-Fatigue median [interquartile range]; EG, baseline $43[43 \text{ to } 49]$, post-intervention $47[38 \text{ to } 52]$; CG, baseline $39[26 \text{ to } 40]$, post-intervention $38[28 \text{ to } 42]$; $p=0.82$ for between-group difference) and feelings of anxiety (HADS: mean \pm SD anxiety score; EG, baseline 3 ± 2 , post-intervention 5 ± 4 ; CG, baseline 2 ± 2 , post-intervention 4 ± 5 ; $p=0.17$ for between-group difference) and depression (HADS: mean \pm SD depression score; EG, baseline 2 ± 2 , post-intervention 4 ± 5 ; CG, baseline 3 ± 3 , post-intervention 4 ± 3 ; $p=0.40$ for between-group difference).

No between-group differences were observed in any measure of lung function (mean difference, 95% CI for between-group difference in change from baseline to post-intervention: FEV_1 $-0.09[-0.22 \text{ to } 0.03]\text{L}$;

FVC -0.12[-0.43 to 0.18]L; total lung capacity -0.03[-0.61 to 0.54]L and single breath diffusing capacity for carbon monoxide -1.4[-3.3 to 0.6].

Discussion

This RCT evaluated the effect of supervised exercise training in people following curative intent treatment for NSCLC. In this population, an 8-week programme of supervised exercise training improved exercise capacity over and above any change seen in the CG. Our finding that supervised exercise training improved exercise capacity extends the findings of a Cochrane systematic review³⁵ and a recently published RCT³⁶ by demonstrating improvements in both field- and laboratory-based tests of exercise capacity. Regarding physical activity and sedentary behaviour, peripheral muscle force, HRQoL, fatigue, feelings of anxiety and depression and lung function, no between-group differences were observed. The use of concealed computer generated randomisation sequence together with blinding of the outcome assessor and the analysis of data according to intention-to-treat principle were some of the strengths of this study.

Effects of the supervised exercise training programme

Exercise capacity

This study demonstrated between-group differences in favour of the EG in three cardiopulmonary variables collected during the CPET and the 6MWD. We acknowledge that the between-group difference in VO_{2peak} , expressed as $L \cdot min^{-1}$, was the result of both a modest increase in the EG and a small decrease in the CG. Nevertheless, the between-group difference in VO_{2peak} following completion of the exercise training programme is of particular importance given that VO_{2peak} is a predictor of mortality in people undergoing treatment for NSCLC³⁷. Although this study did not aim to elucidate the mechanisms underpinning this improvement in exercise capacity, the lack of change in lung function suggests that changes in exercise capacity were most likely mediated by conditioning of the cardiovascular system or peripheral muscles. Our data demonstrating between-group differences, in favour of the EG, in O_2 pulse and AT supports this contention. Improvements in O_2 pulse and AT suggest that exercise training improved exercise capacity by increasing stroke volume and enhancing the oxidative capacity of the exercising muscles³¹.

A between-group difference in favour of the EG was also demonstrated in 6MWD. The magnitude of this difference was 52m, which exceeds the minimal important difference of the 6MWD that has been recently reported for people with lung cancer (22-42m)³⁸. In people with NSCLC, an increase in 6MWD following exercise training is an important finding because this measure appears to be a valuable prognostic indicator in this population³⁹. Maintenance of these improvements in exercise capacity was not investigated in this RCT. As benefits of exercise training diminish over time⁴⁰, future studies should investigate strategies to maintain the improvements.

Secondary outcomes

On completion of the intervention period, no between-group differences were observed in any of the other measures. The lack of between-group difference in physical activity or sedentary behaviour following exercise training in people following lung resection for NSCLC is in agreement with data from a previous RCT⁴¹ and is likely to be due to the minimal impairment in these measures at baseline. The baseline values of daily steps reported in the current study is also similar to the results of an earlier work that assessed people within four weeks of hospital discharge following lobectomy for NSCLC (7978±4486 steps/day)⁴². Further, a recent study published by our group has demonstrated that people following curative intent treatment for NSCLC spend as much time in moderate-to-vigorous intensity physical activity and sedentary behaviour as their healthy counterparts⁴³.

Our study did not demonstrate any change in isometric quadriceps muscle force or handgrip force. The reasons for this may relate to: (i) insufficient training load to induce change; (ii) lack of statistical power, especially for changes in quadriceps force as only a small number of participants chose to attend the University for this assessment; and (iii) minimal impairment in these measures at baseline. The lack of improvement in muscle force demonstrated in this study is in agreement with a previous RCT⁴⁴ which investigated the effect of a 12-week training programme initiated immediately following surgery for NSCLC. Similar to the current study, this earlier study was also likely to be underpowered to demonstrate a between-group difference in quadriceps force. A larger RCT (n=45) of resistance exercise training for people in stage I to III lung cancer demonstrated significant between-group differences in quadriceps torque on completion of a 12-week training programme⁴⁵. Of note, this RCT only included people who presented with quadriceps muscle weakness, defined as either a quadriceps muscle force <70% of their

predicted value or a decrement of 10% in quadriceps muscle force following lung cancer treatment⁴⁵. Therefore, in people with lung cancer, resistance training may be most effective in those with demonstrated muscle weakness.

Our results showing no difference in HRQoL on completion of exercise training in people following lung resection NSCLC corroborate findings of earlier studies^{14, 44}. Although we used both a generic and two disease-specific HRQoL questionnaires, the latter of which were expected to be more responsive than the questionnaires used in earlier work⁴⁴, we were unable to demonstrate any effect of exercise training on HRQoL. The current study also demonstrated no differences in fatigue or feelings of anxiety and depression on completion of exercise training. Similar to measures of peripheral muscle force, it is possible that the lack of improvement in HRQoL, fatigue and feelings of anxiety and depression may be attributable to near normal baseline scores, suggesting minimal impairment in these domains. Specifically, in the EG, the physical component score (PCS) and the mental component score (MCS) of the SF-36 at baseline were similar to the mean normal scores of 50 ± 10 (PCS) and 53 ± 10 (MCS) reported for the Australian population⁴⁶. Likewise, at baseline, participants did not present with fatigue²¹, and had low scores for feelings of anxiety and depression (HADS anxiety and depression scores ≤ 7). This suggests that there was little scope for improvement with exercise training.

Study limitations

Recruitment of participants to this study was challenging. Many of the eligible people following curative intent treatment for NSCLC did not consent due to difficulties with travelling to the hospital (if allocated to the EG) or due to other demands on their time. As this was a pilot study, it is possible that the lack of between-group differences in many of the outcomes reflects inadequate statistical power. However, we have provided an estimate of effect of exercise training for each of the study outcomes which is useful for future sample size calculations. We also acknowledge that adherence to the exercise training was low which is likely to have compromised the effectiveness of the programme.

Conclusions

An 8-week programme of supervised exercise training increased exercise capacity in people following curative intent treatment for NSCLC. No changes were observed in physical activity and sedentary behaviour, peripheral muscle force, HRQoL, fatigue, feelings of anxiety and depression and lung function. Although this study had many strengths in its design including using a concealed computer generated randomisation sequence, blinding of outcome assessors and analysing the data according to intention-to-treat principle, it was a pilot study and the ability to detect changes in outcomes other than exercise capacity is likely to have been influenced by the small sample size and poor adherence to exercise training.

Acknowledgements

VC is supported by the Curtin Strategic International Research Scholarship (CSIRS) and Lung Institute of Western Australia (LIWA) PhD Top-up Scholarship. The study received funding from Sir Charles Gairdner Hospital Research Advisory Committee (grant number: 2011/12/013).

Specific Contributions of each author

VC: Literature search, data collection, study design, analysis of data, manuscript preparation and review of manuscript.

SJ and NC: Data collection, study design and review of manuscript.

KG, MP and LHS: Data collection and review of manuscript.

KH: Data collection, study design, analysis of data, manuscript preparation and review of manuscript.

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136(5):E359-386.
2. AIHW and Cancer Australia 2011. Lung cancer in Australia an overview. Cat. no. CAN 58. Canberra AIHW
3. Sher T, Dy GK, Adjei AA. Small cell lung cancer. *Mayo Clin Proc* 2008;83(3):355-367.
4. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143(5 Suppl):e278S-313S.
5. Jones LW. Physical activity and lung cancer survivorship. *Recent Results Cancer Res* 2011;186:255-274.
6. Win T, Groves AM, Ritchie AJ, Wells FC, Cafferty F, Laroche CM. The effect of lung resection on pulmonary function and exercise capacity in lung cancer patients. *Respir Care* 2007;52(6):720-726.
7. Cavalheri V, Jenkins S, Cecins N, Gain K, Phillips M, Sanders LH, et al. Impairments after curative intent treatment for non-small cell lung cancer: a comparison with age and gender-matched healthy controls. *Respir Med* 2015;109(10):1332-1339.
8. Poghosyan H, Sheldon LK, Leveille SG, Cooley ME. Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: A systematic review. *Lung Cancer* 2013;81(1):11-26.
9. Balduyck B, Hendriks J, Lauwers P, Sardari Nia P, Van Schil P. Quality of life evolution after lung cancer surgery in septuagenarians: a prospective study. *Eur J Cardiothorac Surg* 2009;35(6):1070-1075; discussion 1075.
10. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2015;2:CD003793.
11. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. *Cochrane Database Syst Rev* 2014;10:CD006322.

12. Schmitz KH, Holtzman J, Courneya KS, Masse LC, Duval S, Kane R. Controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2005;14(7):1588-1595.
13. McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. *CMAJ* 2006;175(1):34-41.
14. Cavalheri V, Tahirah F, Nonoyama M, Jenkins S, Hill K. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. *Cochrane Database Syst Rev* 2013;7:CD009955.
15. Jenkins S, Cecins N, Camarri B, Williams C, Thompson P, Eastwood P. Regression equations to predict 6-minute walk distance in middle-aged and elderly adults. *Physiother Theory Pract* 2009;25(7):516-522.
16. Holland AE, Spruit MA, Troosters T, Puhan MA, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. *Eur Respir J* 2014;44(6):1428-1446.
17. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473-483.
18. Cella DF, Bonomi AE, Lloyd SR, Tulskey DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. *Lung Cancer* 1995;12(3):199-220.
19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85(5):365-376.
20. Snaith RP. The Hospital Anxiety And Depression Scale. *Health Qual Life Outcomes* 2003;1:29.
21. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. *J Pain Symptom Manage* 1997;13(2):63-74.

22. Spruit MA, Sillen MJ, Groenen MT, Wouters EF, Franssen FM. New normative values for handgrip strength: results from the UK Biobank. *Journal of the American Medical Directors Association* 2013;14(10):775 e775-711.
23. Hill K, Dolmage TE, Woon L, Goldstein R, Brooks D. Measurement properties of the SenseWear armband in adults with chronic obstructive pulmonary disease. *Thorax* 2010;65(6):486-491.
24. Cavalheri V, Donaria L, Ferreira T, Finatti M, Camillo CA, Cipulo Ramos EM, et al. Energy expenditure during daily activities as measured by two motion sensors in patients with COPD. *Respir Med* 2011;105(6):922-929.
25. Cindy Ng LW, Jenkins S, Hill K. Accuracy and responsiveness of the stepwatch activity monitor and ActivPAL in patients with COPD when walking with and without a rollator. *Disabil Rehabil* 2012;34(15):1317-1322.
26. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc* 2011;43(7):1334-1359.
27. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J* 2005;26(2):319-338.
28. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, et al. Standardisation of the measurement of lung volumes. *Eur Respir J* 2005;26(3):511-522.
29. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J* 2005;26(4):720-735.
30. American Thoracic Society/European Respiratory S. ATS/ERS Statement on respiratory muscle testing. *Am J Respir Crit Care Med* 2002;166(4):518-624.
31. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2003;167(2):211-277.
32. Blackie SP, Fairbairn MS, McElvaney GN, Morrison NJ, Wilcox PG, Pardy RL. Prediction of maximal oxygen uptake and power during cycle ergometry in subjects older than 55 years of age. *Am Rev Respir Dis* 1989;139(6):1424-1429.

33. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. *Eur Respir J* 1997;10(2):417-423.
34. Jenkins S, Hill K, Cecins NM. State of the art: how to set up a pulmonary rehabilitation program. *Respirology* 2010;15(8):1157-1173.
35. Cavalheri V, Tahirah F, Nonoyama M, Jenkins S, Hill K. Exercise training for people following lung resection for non-small cell lung cancer - A Cochrane systematic review. *Cancer Treat Rev* 2014;40(4):585-594.
36. Edvardsen E, Skjonsberg OH, Holme I, Nordsletten L, Borchsenius F, Anderssen SA. High-intensity training following lung cancer surgery: a randomised controlled trial. *Thorax* 2015;70(3):244-250.
37. Jones LW, Watson D, Herndon JE, 2nd, Eves ND, Haithcock BE, Loewen G, et al. Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. *Cancer* 2010;116(20):4825-4832.
38. Granger CL, Holland AE, Gordon IR, Denehy L. Minimal important difference of the 6-minute walk distance in lung cancer. *Chron Respir Dis* 2015.
39. Zarogoulidis P, Kerenidi T, Huang H, Kontakiotis T, Tremma O, Porpodis K, et al. Six minute walking test and carbon monoxide diffusing capacity for non-small cell lung cancer: easy performed tests in every day practice. *J Thorac Dis* 2012;4(6):569-576.
40. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. *Lancet* 2000;355(9201):362-368.
41. Arbane G, Douiri A, Hart N, Hopkinson NS, Singh S, Speed C, et al. Effect of postoperative physical training on activity after curative surgery for non-small cell lung cancer: a multicentre randomised controlled trial. *Physiotherapy* 2014;100(2):100-107.
42. Novoa N, Varela G, Jimenez MF, Aranda JL. Influence of major pulmonary resection on postoperative daily ambulatory activity of the patients. *Interact Cardiovasc Thorac Surg* 2009;9(6):934-938.
43. Cavalheri V, Jenkins S, Cecins N, Phillips M, Sanders LH, Hill K. Patterns of sedentary behaviour and physical activity in people following curative intent treatment for non-small cell lung cancer. *Chron Respir Dis* 2016;13(1):82-85.

44. Arbane G, Tropman D, Jackson D, Garrod R. Evaluation of an early exercise intervention after thoracotomy for non-small cell lung cancer (NSCLC), effects on quality of life, muscle strength and exercise tolerance: Randomised controlled trial. *Lung Cancer* 2011;71(2):229-234.
45. Salhi B, Huysse W, Van Maele G, Surmont VF, Derom E, van Meerbeeck JP. The effect of radical treatment and rehabilitation on muscle mass and strength: a randomized trial in stages I-III lung cancer patients. *Lung Cancer* 2014;84(1):56-61.
46. Hawthorne G, Osborne RH, Taylor A, Sansoni J. The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms. *Qual Life Res* 2007;16(4):661-673.

Tables

Table 1: Characteristics at baseline.

Variables <i>mean (SD)</i>	Total Sample (n=17)		Exercise group (n=9)		Control group (n=8)	
Age (yr)	67 (9)		66 (10)		68 (9)	
Height (cm)	165 (12)		164 (14)		166 (11)	
Weight (kg)	72 (21)		67 (14)		77 (27)	
BMI (kg·m ⁻²)	26 (6)		25 (5)		27 (6)	
Smoking (pack·years)	35 (15)		49 (27)		35 (24)	
FEV ₁ (L)	1.65 (0.49)		1.53 (0.47)		1.78 (0.50)	
FEV ₁ (%pred)	66 (17)		61 (17)		71 (15)	
FVC (L)	2.68 (0.69)		2.51 (0.76)		2.87 (0.58)	
FVC (%pred)	80 (12)		74 (11)		86 (10)	
FEV ₁ /FVC (%)	62 (12)		62 (14)		62 (11)	
TLC (L)	4.73 (1.19)		4.58 (1.56)		4.91 (0.64)	
TLC (%pred)	86 (14)		82 (16)		90 (12)	
FRC (L)	2.94 (0.78)		2.87 (1.00)		3.02 (0.47)	
FRC (%pred)	97 (20)		94 (20)		100 (21)	
D _L CO (ml·min ⁻¹ ·mmHg ⁻¹)	13.7 (3.6)		12.8 (3.3)		14.7 (3.8)	
D _L CO (%pred)	53 (12)		49 (11)		57 (13)	
MVV (L·min ⁻¹)	62 (21)		60 (25)		64 (28)	
MVV (%pred)	63 (16)		59 (15)		67 (18)	
	n	%	n	%	n	%
Gender, male/female	5/12	29/71	3/6	30/70	2/6	25/75
COPD	9	53	5	56	4	50
Type of NSCLC						
Adenocarcinoma	10	59	5	56	5	63
Squamous cell carcinoma	6	35	4	44	2	25
Large cell carcinoma	1	6	0	0	1	12
NSCLC stage						
I	14	82	7	78	7	88
II	2	12	2	22	0	0
IIIA	1	6	0	0	1	12
Types of surgery						
Open	8	47	4	44	4	50
VATS	9	53	5	56	4	50
Adjuvant chemotherapy	2	12	1	11	1	12

BMI: Body-mass index; COPD: Chronic obstructive pulmonary disease; D_LCO: single breath diffusing capacity for carbon monoxide; FEV₁: Forced expiratory volume in one second; FRC: Functional residual capacity; FVC: Forced vital capacity; MVV: Maximum voluntary ventilation; NSCLC: Non-small cell lung cancer; SD: Standard deviation; TLC: Total lung capacity; VATS: Video-assisted thoracoscopic surgery.

Table 2: Baseline and post-intervention measures of exercise capacity.

Variable <i>mean ± SD</i>	Exercise group			Control group			<i>F; p value</i> <i>within-</i> <i>group</i>	MD [95% CI] <i>Between-</i> <i>group</i>	<i>F; p value</i> <i>between-</i> <i>group</i>
	Baseline	Post-intervention	MD [95% CI]	Baseline	Post-intervention	MD [95% CI]			
Exercise capacity (CPET)	<i>n</i>=6	<i>n</i>=6		<i>n</i>=8	<i>n</i>=8				
VO _{2peak} (L·min ⁻¹)	0.96±0.22	1.09±0.28	0.14 [-0.01 to 0.28]	1.08±0.40	1.03±0.30	-0.05 [-0.15 to 0.05]	1.5; 0.24	0.2 [0.03 to 0.33]	7.2; 0.02
VO _{2peak} (ml·kg ⁻¹ ·min ⁻¹)	15.7±3.1	17.0±2.5	1.3 [-0.1 to 1.8]	13.9±2.6	13.3±2.1	-0.5 [-2.1 to 1.0]	0.7; 0.41	1.8 [-0.1 to 3.7]	4.4; 0.06
VO _{2peak} (%pred)	62±18	70±21	8 [2 to 15]	64±17	62±13	-2 [-9 to 5]	2.8; 0.12	10 [2 to 19]	6.7; 0.02
Wmax (W)	72±28	77±26	5 [-6 to 17]	77±32	68±21	-9 [-24 to 7]	0.1; 0.73	14 [-5 to 33]	2.6; 0.13
Wmax (%pred)	73±25	78±30	6 [-4 to 15]	69±15	64±14	-5 [-18 to 8]	0.0; 0.90	10 [-6 to 26]	2.0; 0.19
BORGd CPET	6.8±2.0	6.8±1.7	0.0 [-3.1 to 3.1]	5.8±3.0	6.1±1.7	0.4 [-1.0 to 1.7]	0.1; 0.77	-0.4 [-3.0 to 2.3]	0.1; 0.77
BORGf CPET	5.0±2.5	6.8±1.9	1.8 [-1.6 to 5.3]	7.4±2.1	6.9±2.0	-0.5 [-3.1 to 2.1]	0.6; 0.46	2.3 [-1.5 to 6.1]	1.8; 0.21
Nadir SpO ₂ (%)	94±2	94±4	1 [-4 to 5]	94±6	95±3	1 [-6 to 7]	0.2; 0.64	-0 [-8 to 7]	0.0; 0.99
HRmax (bpm)	130±20	124±19	-6 [-13 to 2]	127±18	128±18	1 [-15 to 17]	0.3; 0.61	-7 [-24 to 11]	0.6; 0.44
BR (%)	27±12	28±13	1 [-14 to 16]	32±14	43±10	11 [-0 to 23]	2.7; 0.12	-10 [-27 to 6]	1.9; 0.19
O ₂ pulse (ml·beat ⁻¹)	7±2	9±2	2 [0 to 2]	8±3	8±3	0 [-1 to 1]	3.4; 0.09	2 [1 to 3]	8.7; 0.01
AT (% VO _{2peak})	60±9	71±8	11 [7 to 15]	63±10	63±10	0 [-8 to 9]	6.4; 0.03	11 [1 to 21]	5.9; 0.03
VEmax/MVV (%)	73±12	72±13	-1 [-16 to 14]	68±14	58±12	-9 [-20 to 1]	2.3; 0.15	0.1 [-0.1 to 0.3]	1.4; 0.26
Exercise capacity (6MWT)	<i>n</i>=6	<i>n</i>=6		<i>n</i>=7	<i>n</i>=7				
6MWD (m)	540±71	585±77	45 [6 to 83]	477±78	469±105	-8 [-36 to 20]	3.9; 0.07	52 [12 to 93]	8.1; 0.02
6MWD (%pred)	88±9	96±5	8 [3 to 14]	77±11	76±16	-1 [-6 to 4]	5.4; 0.04	9 [3 to 16]	9.1; 0.01
BORGd 6MWT	3.3±2.0	2.8±1.2	-0.5 [-2.5 to 1.5]	3.4±1.5	3.7±2.4	0.3 [-1.2 to 1.9]	0.2; 0.89	-0.9 [-3.0 to 1.3]	0.8; 0.40
BORGf 6MWT	1.5±1.9	2.3±1.8	0.8 [-1.3 to 2.8]	3.4±1.9	4.1±1.6	0.7 [-1.2 to 2.6]	1.6; 0.22	0.0 [-2.4 to 2.5]	0.0; 0.97
Nadir SpO ₂ (%)	92±4	92±3	0 [-2 to 1]	92±2	93±1	1 [-0 to 2]	0.6; 0.46	-1 [-2 to 1]	1.5; 0.25
Peak HR (bpm)	125±16	126±15	1 [-13 to 15]	122±11	121±18	0 [-9 to 8]	0.0; 0.95	2 [-12 to 15]	0.1; 0.80

6MWD: Six-minute walk distance; 6MWT: Six-minute walk test; AT: Anaerobic threshold as a percentage of the VO_{2peak}; BORGd: Dyspnoea; BORGf: Fatigue; BR: Breathing reserve; CI: Confidence interval; CPET: Cardiopulmonary exercise test; HR: Heart rate; HRmax: Maximal heart rate; MD: Mean difference; O₂ pulse: Oxygen pulse; SD: Standard deviation; SpO₂: Arterial oxygen saturation measured via pulse oximetry; VEmax/MVV: Maximum minute ventilation, maximum voluntary ventilation ratio; VO_{2peak}: Peak rate of oxygen consumption; Wmax: Maximum work rate.

Table 3: Baseline and post-intervention measures of physical activity, sedentary behaviour and peripheral muscle force.

Variable	Exercise group (n=8)			Control group (n=8)			<i>F; p value</i>	MD [95% CI]	<i>F; p value</i>
	Baseline	Post-intervention	MD [95% CI]	Baseline	Post-intervention	MD [95% CI]			
Physical activity and sedentary behaviour									
mean ± SD							<i>within-group</i>	<i>between-group</i>	<i>between-group</i>
Number of days wearing monitor	6.6±0.5	6.5±0.5	-0.0 [-1.0 to 1.0]	6.3±1.1	6.5±1.0	-0.2 [-1.1 to 1.2]	0.9; 0.35	0.2 [-0.8 to 1.3]	0.24; 0.63
Monitor wear time (hr/day)	13.8±1.2	13.0±1.1	-0.8 [-2.0 to 0.4]	13.3±1.4	13.2±1.5	-0.4 [-1.3 to 0.5]	2.7; 0.12	-0.8 [-1.8 to 0.2]	1.8; 0.20
Stepwatch activity monitor									
Daily steps	9357±4195	9816±4382	460 [-153 to 1073]	6282±2331	8020±3864	1738 [-455 to 3931]	5.2; 0.04	-1278 [-3344 to 786]	1.8; 0.21
SenseWear armband									
Sedentary behaviour (%)	62±16	59±16	-3 [-7 to 1]	74±12	67±14	-7 [-13 to 1]	7.3; 0.02	4 [-4 to 11]	1.1; 0.31
Light intensity PA (%)	21±11	25±11	4 [-3 to 11]	20±7	26±11	6 [-1 to 12]	6.9; 0.02	4 [-10 to 6]	0.3; 0.58
Moderate-to-vigorous intensity PA (%)	17±13	16±8	-1 [-6 to 4]	6±6	7±4	1 [-3 to 5]	0.3; 0.86	-2 [-7 to 5]	0.3; 0.60
Peripheral muscle force	Baseline	Post-intervention		Baseline	Post-intervention				<i>p value</i>
<i>median [IQR]</i>									<i>between-group</i>
Isometric quadriceps force	n = 5	n = 5		n = 4	n = 4				
Torque (Nm)	101 [70 to 132]	112 [82 to 142]		151 [91 to 238]	153 [101 to 210]				0.536
Torque (%pred)	103 [87 to 160]	114 [100 to 171]		99 [93 to 104]	97 [82 to 114]				0.190
Isometric handgrip force	n = 7	n = 7		n = 8	n = 8				
Torque (Nm)	32 [18 to 34]	33 [20 to 35]		26 [20 to 30]	26 [19 to 31]				0.072
Torque (%pred)	91 [78 to 115]	93 [78 to 127]		97 [83 to 111]	100 [83 to 107]				0.281

%-: Percentage of waking hours; CI: Confidence interval; IQR: Interquartile range; MD: Mean difference; PA: Physical activity; SD: Standard deviation. No within- or between-group differences were observed in physical activity, sedentary behaviour, isometric quadriceps torque or isometric handgrip force. Definitions: Sedentary behaviour – energy expenditure ≤ 1.5 metabolic equivalent units (MET); Light intensity PA – energy expenditure > 1.5 and ≤ 3 MET; Moderate-to-vigorous intensity PA – energy expenditure > 3 MET.

Table 4: Baseline and post-intervention measures of health-related quality of life.

Variable	Exercise group (n=9)			Control group (n=8)			F; p value	MD [95% CI]	F; p value
	Baseline	Post-intervention	MD [95% CI]	Baseline	Post-intervention	MD [95% CI]			
<i>mean ± SD</i>							<i>within-group</i>	<i>between-group</i>	<i>between-group</i>
HRQoL (SF-36)									
PCS [#]	46±6	48±8	2 [-3 to 6]	42±5	40±9	-2 [-7 to 2]	0.0; 0.89	4 [-2 to 10]	1.80; 0.20
MCS [#]	55±6	51±14	-4 [-12 to 5]	46±6	51±8	5 [-2 to 12]	0.1; 0.80	-8 [-18 to 2]	3.2; 0.10
Physical functioning [#]	67±14	74±18	7 [-4 to 18]	52±24	55±23	3 [-8 to 13]	2.1; 0.16	5 [-9 to 19]	0.5; 0.49
Role physical [#]	72±23	69±38	-3 [-22 to 17]	44±14	44±17	0 [-16 to 16]	0.1; 0.81	-3 [-27 to 21]	0.1; 0.81
Bodily pain [#]	62±12	60±26	-2 [-26 to 22]	63±23	56±33	-8 [-34 to 19]	0.4; 0.54	6 [-27 to 38]	0.1; 0.71
General health [#]	72±19	72±26	0 [-15 to 14]	63±19	65±21	3 [-13 to 18]	0.1; 0.80	-3 [-22 to 16]	0.1; 0.73
Vitality [#]	67±18	72±30	-5 [-10 to 20]	52±17	54±17	2 [-7 to 10]	0.7; 0.41	3 [-13 to 20]	0.2; 0.67
Social functioning [#]	78±22	74±35	-4 [-21 to 13]	69±22	73±29	5 [-15 to 25]	0.0; 0.96	-9 [-33 to 15]	0.6; 0.45
Role emotional [#]	88±17	80±29	-8 [-31 to 14]	57±20	68±22	10 [-10 to 31]	0.0; 0.88	-19 [-47 to 9]	2.0; 0.18
Mental health [#]	80±14	73±24	-7 [-23 to 9]	70±18	79±17	9 [-3 to 20]	0.1; 0.81	-15 [-34 to 3]	3.2; 0.09
HRQoL (FACT-L)									
Physical well-being [#]	25±2	24±5	-1 [-4 to 3]	22±5	21±7	-1 [-4 to 2]	0.9; 0.36	0 [-4 to 4]	0.0; 0.91
Social/family well-being [#]	20±8	21±7	0 [-4 to 4]	15±9	19±6	4 [1 to 8]	3.7; 0.07	-4 [-9 to 1]	3.3; 0.09
Emotional well-being [#]	21±2	19±6	-2 [-5 to 1]	18±5	20±4	2 [-1 to 5]	0.0; 0.95	-4 [-8 to 1]	3.6; 0.08
Functional well-being [#]	20±5	21±9	2 [-3 to 6]	13±7	17±8	4 [-5 to 12]	1.8; 0.20	-2 [-11 to 6]	0.3; 0.59
Lung cancer subscale [#]	20±3	22±4	3 [0 to 5]	16±2	20±3	5 [1 to 8]	16.3; 0.01	-2 [-6 to 2]	1.0; 0.33
Total [#]	106±16	107±25	2 [-10 to 14]	83±22	97±21	13 [-1 to 28]	3.6; 0.08	-12 [-29 to 5]	2.2; 0.16
HRQoL (EORTC QLQ-C30)									
Global health status [#]	74±16	75±25	1 [-22 to 24]	66±24	64±22	-2 [-10 to 6]	0.0; 0.91	3 [-20 to 27]	0.1; 0.79
Functional scales [#]	85±9	85±17	0 [-10 to 11]	73±16	76±12	3 [-3 to 9]	0.3; 0.57	-3 [-14 to 9]	0.2; 0.63
Symptoms scales [†]	20±9	17±13	-3 [-15 to 8]	22±11	23±15	1 [-8 to 10]	0.1; 0.77	-4 [-18 to 9]	0.4; 0.52
EORTC LC13 [†]	16±8	14±8	-2 [-10 to 6]	16±9	25±19	9 [-1 to 19]	1.5; 0.23	-11 [-23 to 1]	3.8; 0.07

CI: Confidence interval; EORTC QLQ-C30: The European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core 30; EORTC LC13: Lung Cancer subscale of the EORTC QLQ-C30; FACT-L: The Functional Assessment of Cancer Therapy – Lung scale; MCS: Mental component score; MD: Mean difference; PCS: Physical component score; SD: Standard deviation; SF-36: Medical Outcomes Study short form 36 general health survey. [#]Greater scores reflect better outcome; [†]Lower scores reflect better outcome.

Figure




Figure 1: Study flow diagram.